Pharmacokinetics of doxazosin gastrointestinal therapeutic system after multiple administration in Korean healthy volunteers

Drug Development and Industrial Pharmacy

Volumn 33, Issue 8, 2007, Pages 824-829

  Kwon, Yoon Hee ^a   Gwak, Hye Sun ^a   Yoon, Sun Jung ^b   Chun, In Koo ^b  

^a Ewha Womans University   (South Korea)

^b Dongduk Women's University   (South Korea)

Author keywords

Doxazosin gastrointestinal therapeutic system; High performance liquid chromatography; Pharmacokinetic parameters; Prazosin

Indexed keywords

DOXAZOSIN; DOXAZOSIN MESYLATE; PRAZOSIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; GASTROINTESTINAL TRACT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; KOREA; MALE; NORMAL HUMAN; SEX DIFFERENCE;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; DOXAZOSIN; FEMALE; HALF-LIFE; HUMANS; KOREA; MALE; SEX FACTORS;

EID: 34548299764     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040601012999     Document Type: Article

References (20)

1. Chung, M., Vashi, V., Puente, J., Sweeney, M., & Meredith, P. (1999). Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br. J. Clin. Pharmacol., 48, 678-687.
2. Daae, L. N., & Westlie, L. (1998). A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk. Blood Press., 7, 39-45.
3. Davey, M. J. (1989). Pharmacologic basis for the use of doxazosin in the treatment of essential hypertension. Am. J. Med., 87, 36S-44S.
4. 1-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from to benign prostatic enlargement. BJU Int., 93, 757-762.
5. Elliott, H. L., Meredith, P. A., & Reid, J. L. (1987). Pharmacokinetic overview of doxazosin. Am J. Cardiol., 59, 78G-81G.
6. Fawzy, A., Vashi, V., Chung, M., Dias, N., & Gaffney, M. (1999). Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Urology., 53, 329-335.
7. Fitzpatrick, J. M., & Desgrandchamps, F. (2005). The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia. BJU Int., 95, 575-579.
8. 1-adrenoreceptor antagonists for the treatment of benign prostatic hyperplasia. Expert Opin. Invest. Drugs, 8, 2073-2094.
9. Fulton, B., Wagstaff, A. J., & Sorkin, E. M. (1995). Doxazosin: an update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs, 49, 295-320.
10. Gwak, H. S., & Chun, I. K. (2005). Simplified HPLC method for the determination of prazosin in plasma and its application to single-dose pharmacokinetics. J. Appl. Pharmacol., 13, 90-94.
11. Intl. Conf. on Harmonisation Topic Q 2B, Validation of Analytical Procedures: Methodology, Step 4, Consensus Guideline, 1996.
12. James, S., Chapple, C. R., Phillips, M. I., Greengrass, P. M., Davey, M. J., Turner-Warwick, R. T., Milroy, E. J., & Burnstock, G. (1989). Autoradiographic analysis of alpha-adrenoceptors and muscarinic cholinergic receptors in the hyperplastic human prostate. J. Urol., 142, 438-444.
13. Karnes, H. T., Shiu, G., & Shah, V. P. (1991). Validation of bioanalytical methods. Pharm. Res., 8, 421-426.
14. Kaye, B., Cussans, N. J., Faulkner, J. K., Stopher, D. A., & Reid, J. L. (1986). The metabolism and kinetics of doxazosin in man, mouse, rat and dog. Br. J. Clin. Pharmacol., 21, 19S-25S.
15. Kirby, R. S. (2003). A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU Int., 91, 41-44.
16. Kirby, R., Andersson, K. E., Lepor, H., & Steers, W. D. (2000). Alpha (1)-adrenoreceptor selectivity and the treatment of benign prostatic hyperplasia and lower urinary tract symptoms. Prostate Cancer Prostatic Dis., 3, 76-83.
17. Lepor, H., Kaplan, S. A., Klimberg, I., Mobley, D. F., Fawzy, A., Gaffney, M., Ice, K., & Dias, N. (1997). Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. J. Urol., 157, 525-530.
18. Shapiro, E., Hartanto, V., & Lepor, H. (1992). The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate., 21, 297-307.
19. Sripalakit, P., Nermhom, P., & Saraphanchotiwitthaya, A. (2006). Validation and pharmacokinetic application of a method for determination of doxazosin in human plasma by high-performance liquid chromatography. Biomed. Chromatogr., 20, 729-735.
20. Rubin, P. C., Brunton, J., & Meredith, P. (1980). Determination of the vasodilator UK 33274 by high-performance liquid chromatography using fluorescence detection. J. Chromatogr., 221, 193-195.